Abstract
This open-label, prospective, multicentre, 4-week trial was undertaken to assess the efficacy and tolerability of twice daily levocabastine eye drops (0.5 mg/ml), with sodium cromoglycate nasal spray for the relief of concurrent nasal symptoms if required, in a total of 233 children with seasonal allergic conjunctivitis. No correlation between efficacy, tolerability and age was found. Investigator assessments revealed that the total severity of ocular symptoms decreased by 84 ± 34% in patients < 12 years and 85 ± 30% in those ≥ 12 years, with corresponding reductions in the total severity of ocular findings of 84% in both patient groups over the 4-week treatment period. Global assessments of therapeutic efficacy revealed the effect of therapy on ocular symptoms to be excellent or good in 81% of patients < 12 years and 82% of those ≥ 12 years after 2 weeks of treatment, with corresponding values at the end of the trial of 88% and 82% in the two groups, respectively. Treatment tolerability was considered to be excellent or good by 94% of patients overall. Application site reactions were the most common adverse event associated with ocular levocabastine, occurring in 13% of patients < 12 years and 9% of those ≥ 12 years. Twice daily levocabastine eye drops therefore appear to be effective and well tolerated for the treatment of seasonal allergic conjunctivitis in children.
Full Text
The Full Text of this article is available as a PDF (445.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Abelson M. B., Weintraub D. Levocabastine eye drops: a new approach for the treatment of acute allergic conjunctivitis. Eur J Ophthalmol. 1994 Apr-Jun;4(2):91–101. doi: 10.1177/112067219400400203. [DOI] [PubMed] [Google Scholar]
- Azevedo M., Castel-Branco M. G., Oliveira J. F., Ramos E., Delgado L., Almeida J. Double-blind comparison of levocabastine eye drops with sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis. Clin Exp Allergy. 1991 Nov;21(6):689–694. doi: 10.1111/j.1365-2222.1991.tb03197.x. [DOI] [PubMed] [Google Scholar]
- Bahmer F. A., Ruprecht K. W. Safety and efficacy of topical levocabastine compared with oral terfenadine. Ann Allergy. 1994 May;72(5):429–434. [PubMed] [Google Scholar]
- Bende M., Pipkorn U. Topical levocabastine, a selective H1 antagonist, in seasonal allergic rhinoconjunctivitis. Allergy. 1987 Oct;42(7):512–515. doi: 10.1111/j.1398-9995.1987.tb00374.x. [DOI] [PubMed] [Google Scholar]
- Davies B. H., Mullins J. Topical levocabastine is more effective than sodium cromoglycate for the prophylaxis and treatment of seasonal allergic conjunctivitis. Allergy. 1993 Oct;48(7):519–524. doi: 10.1111/j.1398-9995.1993.tb01108.x. [DOI] [PubMed] [Google Scholar]
- Dechant K. L., Goa K. L. Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. Drugs. 1991 Feb;41(2):202–224. doi: 10.2165/00003495-199141020-00006. [DOI] [PubMed] [Google Scholar]
- Odelram H., Björkstén B., af Klercker T., Rimås M., Kjellman N. I., Blychert L. O. Topical levocabastine versus sodium cromoglycate in allergic conjunctivitis. Allergy. 1989 Aug;44(6):432–436. doi: 10.1111/j.1398-9995.1989.tb04175.x. [DOI] [PubMed] [Google Scholar]
- Stokes T. C., Feinberg G. Rapid onset of action of levocabastine eye-drops in histamine-induced conjunctivitis. Clin Exp Allergy. 1993 Sep;23(9):791–794. doi: 10.1111/j.1365-2222.1993.tb00368.x. [DOI] [PubMed] [Google Scholar]
- Topical levocabastine compared with oral loratadine for the treatment of seasonal allergic rhinoconjunctivitis. Swedish GP Allergy Team. Allergy. 1994 Sep;49(8):611–615. doi: 10.1111/j.1398-9995.1994.tb00127.x. [DOI] [PubMed] [Google Scholar]
- Vermeulen J., Mercer M. Comparison of the efficacy and tolerability of topical levocabastine and sodium cromoglycate in the treatment of seasonal allergic rhinoconjunctivitis in children. Pediatr Allergy Immunol. 1994 Nov;5(4):209–213. doi: 10.1111/j.1399-3038.1994.tb00241.x. [DOI] [PubMed] [Google Scholar]
